Meissa Vaccines
San Francisco
About Meissa Vaccines
Meissa Vaccines is a start-up pharmaceutical development company focused on the in-licensing and advancement of vaccines for respiratory syncytial virus (RSV, the largest unmet respiratory medical need in pediatrics) and rhinovirus (leading cause of infectious disease worldwide). Their passion is child health, but our vaccine programs have the potential to benefit multiple age groups directly and indirectly. Successful vaccines for respiratory syncytial virus and rhinovirus would have widespread benefits for society and families. These include reducing the burden of acute lower respiratory tract disease, reducing colds, reducing acute asthma exacerbations caused by these viruses, and alleviating missed school and work.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $33.4M
- Funding stage: Early Stage Venture
- Last round: Series A (Sep 2019)
- Website: meissavaccines.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Health Care
Social Profiles
Canonical: https://fsome.com/organization/meissa-vaccines-60166 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.